DelMar Pharmaceuticals Announces Presentation at the European Association of Neuro-Oncology (EANO) Annual Meeting in October 2016

Jul 21, 2016

DelMar Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on July 14

Jul 13, 2016

DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ

Jul 11, 2016

DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting

Jun 6, 2016

DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme

May 25, 2016

DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting

May 19, 2016

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update

May 13, 2016

DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares

May 5, 2016

FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer

Apr 21, 2016

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting

Apr 19, 2016